MSA Safety
- Country
- 🇪🇬Egypt
- Ownership
- -
- Employees
- 1.3K
- Market Cap
- -
- Introduction
Mineros SA is a Latin American gold mining company. The company has a diversified asset base, with mines in Colombia, Nicaragua and Argentina and a pipeline of development and exploration projects throughout the region. In Colombia, Nechi Aluvial is a mining property located in the Lower Cauca Region of Antioquia, in northwestern Colombia. In Nicaragua, it owns Hemco, a mining operation located in Bonanza, a municipality in the Caribbean Coast, in the northeastern part of the country, where it has an underground mine and an artisanal mining program. The property in Argentina, Gualcamayo has an open pit and an underground operation. In Chile, it has the La Pepa Greenfield project with Yamana, in the region of Copiapo, in the northern part of the country.
BioArctic Expands Exidavnemab Phase 2a Trial to Include Multiple System Atrophy Patients
Regulatory authorities in Spain and Poland have approved the inclusion of Multiple System Atrophy (MSA) patients in BioArctic's ongoing EXIST Phase 2a trial of exidavnemab, an alpha-synuclein antibody.
Lundbeck Presents Phase II Data for Amlenetug in Multiple System Atrophy at International Congress
Lundbeck presented results from the AMULET phase II trial investigating amlenetug, a monoclonal antibody targeting α-synuclein, as a potential treatment for multiple system atrophy (MSA).
Cytora's Stem Cell Therapy Shows Promising Results for Diabetic Foot Ulcers in Phase 1/2a Trial
Cytora's novel stem cell therapy hOMSC200, derived from human oral mucosa stem cells, demonstrated safety and efficacy in treating chronic diabetic foot ulcers with no immune rejection in a Phase 1/2a trial.
Ampreloxetine Shows Promise for Neurogenic Orthostatic Hypotension in MSA Patients Without Worsening Supine Hypertension
New analyses from Theravance Biopharma's Phase 3 trials demonstrate ampreloxetine's selective mechanism of action and durable target engagement in treating neurogenic orthostatic hypotension (nOH) in multiple system atrophy patients.
Yoda Therapeutics Initiates Phase 2 Trial of YA-101 for Multiple System Atrophy
Yoda Therapeutics has dosed the first patient in a Phase 2 trial of YA-101, an AI-pioneered novel chemical entity designed to treat Multiple System Atrophy (MSA) by inhibiting neuroinflammation and enhancing neural plasticity.
FDA Grants Orphan Drug Designation to BioArctic's Exidavnemab for Multiple System Atrophy
The US FDA has granted orphan drug designation to exidavnemab, BioArctic's monoclonal antibody targeting alpha-synuclein aggregates, for the treatment of Multiple System Atrophy.